In contrast, women with triple-negative breast cancers [TNBC (i.e., ER-, PR-, and HER2-)] are typically associated with less favorable prognosis [35, 36] and account for about 10–20 % of breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.